A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer

Oncology

Volumn 80, Issue 3-4, 2011, Pages 175-180

  Yi, Jun Ho ^a   Lee, Jeeyun ^a   Park, Se Hoon ^a   Lee, Kyu Taek ^b   Lee, Jong Kyun ^b   Lee, Kwang Hyuck ^b   Choi, Dong Wook ^b   Choi, Seong Ho ^b   Heo, Jin Seok ^b   Lim, Do Hoon ^a   Park, Young Suk ^a   Lim, Ho Yeong ^a   Kang, Won Ki ^a   Park, Keunchil ^a   Park, Joon Oh ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gastroenterology Department of Medicine ^*  (South Korea)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer; Prognostic model

Indexed keywords

C REACTIVE PROTEIN; CAPECITABINE; CISPLATIN; DOCETAXEL; ERLOTINIB; GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; FEMALE; HAZARD RATIO; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ASCITES; C-REACTIVE PROTEIN; DEOXYCYTIDINE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SERUM ALBUMIN; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79959476726     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328449     Document Type: Article

References (26)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413. (Pubitemid 27251144)
2. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966. (Pubitemid 46972777)
3. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME: Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008; 12: 1193-1201.
4. Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W, Herrmann R: CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008; 9: 132-138.
5. Moses AG, Maingay J, Sangster K, Fearon KC, Ross JA: Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 2009; 21: 1091-1095.
6. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, Rahman SH: Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2009; 35: 605-610.
7. Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T, Tanaka S, Nakaizumi A, Salem AA, Ueda R, Yamao K: Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol 2008; 23: 1292-1297.
8. Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A, Iwasa S, Kojima Y: Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol 2008; 38: 755-761.
9. Ueno H, Okada S, Okusaka T, Ikeda M: Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 2000; 59: 296-301.
10. Mahmoud FA, Rivera NI: The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 2002; 4: 250-255.
11. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002; 420: 860-867. (Pubitemid 36019639)
12. Siddiqui A, Heinzerling J, Livingston EH, Huerta S: Predictors of early mortality in veteran patients with pancreatic cancer. Am J Surg 2007; 194: 362-366. (Pubitemid 47212033)
13. Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, Park JO, Park YS, Lim HY, Sohn TS, Noh JH, Heo JS, Park CK, Kim S, Kang WK: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol 2007; 18: 886-891. (Pubitemid 47054086)
14. Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, Cervera E, Mohar-Betancourt A: Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol 2007; 14: 381-389. (Pubitemid 46175279)
15. Boonpipattanapong T, Chewatanakornkul S: Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol 2006; 40: 592-595. (Pubitemid 44259763)
16. Park MJ, Lee J, Hong JY, Choi MK, Yi JH, Lee SJ, Oh SJ, Ahn JS, Park K, Ahn MJ: Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment. Cancer 2009; 115: 1518-1530.
17. Zhang Y, Dang C, Ma Q, Chen W, Nagata K: Predictors of systemic chemotherapy contraindication in pancreatic cancer patients with distant metastasis. Hepatogastroenterology 2007; 54: 254-259. (Pubitemid 46511687)
18. Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, Fujita Y, Uchiyama K, Yamaue H: Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma. Langenbecks Arch Surg 2009; 394: 249-253.
19. Papadoniou N, Kosmas C, Gennatas K, Polyzos A, Mouratidou D, Skopelitis E, Tzivras M, Sougioultzis S, Papastratis G, Karatzas G, Papalambros E, Tsavaris N: Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. Anticancer Res 2008; 28: 543-549. (Pubitemid 351362868)
20. Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004; 5: 219-228. (Pubitemid 38391217)
21. Dittert DD, Kielisch C, Alldinger I, Zietz C, Meyer W, Dobrowolski F, Saeger HD, Baretton GB: Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis. Hum Pathol 2008; 39: 1002-1010.
22. Einama T, Kagata Y, Tsuda H, Morita D, Ogata S, Ueda S, Takigawa T, Kawarabayashi N, Fukatsu K, Sugiura Y, Matsubara O, Hatsuse K: High-level Skp2 expression in pancreatic ductal adenocarcinoma: correlation with the extent of lymph node metastasis, higher histological grade, and poorer patient outcome. Pancreas 2006; 32: 376-381. (Pubitemid 43772193)
23. Nakata K, Ohuchida K, Nagai E, Hayashi A, Miyasaka Y, Kayashima T, Yu J, Aishima S, Oda Y, Mizumoto K, Tanaka M, Tsuneyoshi M: LMO2 is a novel predictive marker for a better prognosis in pancreatic cancer. Neoplasia 2009; 11: 712-719.
24. Lee J, Jang KT, Ki CS, Lim T, Park YS, Lim HY, Choi DW, Kang WK, Park K, Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109: 1561-1569. (Pubitemid 46595692)
25. Conroy T, Desseigne F, Ychou M: Randomized phase III trial comparing FOLFIRINOX (F:5FU/leucovorin [LV], irinotecan [I], and oxaliplatin[O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results for the PRODIGE4/ACCORD 11 trial (abstract 4010). J Clin Oncol 2010; 28(suppl):303s.
26. Garber K: Stromal depletion goes on trial in pancreatic cancer. J Natl Cancer Inst 2010; 102: 448-450.